Strategic partnership, setting sail for a new era: Warm congratulations to BioDetect and Oumeng Medical for reaching a nationwide exclusive general agency strategic cooperation

The 19th Academic Conference on Laboratory Medicine of the Chinese Medical Association was grandly held today. At the conference, BioDetect and Oumeng Medical co.ltd jointly announced that the two sides have officially reached a national exclusive general agent strategic cooperation. From now on, Oumeng Medical  will become the only general agent in Chinese Mainland for all line respiratory pathogen diagnosis products of Boditai. This cooperation marks the integration of advantageous resources between the two sides, the joint deepening of China's respiratory disease diagnosis market, the provision of accurate and efficient one-stop solutions for clinical use, and the promotion of the prevention and treatment of respiratory infectious diseases in China.

Respiratory infectious diseases is one of the most common diseases in the world, with a wide range of pathogens and complex clinical manifestations. Rapid and accurate pathogen diagnosis is crucial for guiding clinical medication and precise treatment.

As a high-tech enterprise focusing on innovative diagnostic technology, BioDetect has developed multiple diagnostic products for respiratory pathogens. Based on the advanced molecular multi joint detection platform, Boditai can quickly diagnose dozens of common and new respiratory pathogens including COVID-19, influenza A and B, respiratory syncytial virus, mycoplasma pneumoniae, etc. at one time, with high sensitivity, high specificity and high throughput, which has significantly improved the diagnostic efficiency.

As a well-known enterprise that has been deeply involved in the Chinese market for many years, Oumeng Medical has a mature marketing network and professional market service team covering hospitals, disease control centers, and third-party testing institutions at all levels across the country. With a profound understanding of clinical needs and excellent market expansion capabilities, Omon has successfully introduced multiple cutting-edge diagnostic products into the Chinese market and gained widespread recognition from the industry and customers.

BioDetect's technological advantages are deeply integrated with Oumeng Medical network to jointly create a one-stop solution for respiratory pathogen diagnosis. With the characteristics of multiple technology platforms, multiple diagnostic indicators, and flexible applications, relying on the complementary advantages of multiple methodologies, we solve clinical pain points and build a complete diagnosis and treatment path of "outpatient screening+inpatient diagnosis+home monitoring" from rapid screening to accurate diagnosis, and then to efficacy evaluation, providing more efficient, reliable, and suitable diagnostic choices for medical institutions at different levels.

BioDetect& Oumeng Medical's "one-stop solution for respiratory pathogens"

Release on site

BioDetect Molecular Multi Joint Inspection Series: Six Joint Inspection of Upper and Lower Respiratory Tract

                                                                                                             BioDetect  Immunoassay Antigen Rapid Test Series:

Influenza A and B, Mycoplasma pneumoniae, Syncytial virus, Adenovirus,

Rapid Covid-19